Venetoclax as Part of Pre-Transplant Chemotherapy
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 324 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Chemotherapy
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1571
- NCT Identifier
- NCT04708054
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.